Category: Money Tips Date: 2006-12-02
Source: Industrial Securities Author: Chen Yi Ang
Monday to highlight the market is very hot, G Merlin, G Urban, G 900, etc. Shanghai local shares hit daily limit and this has driven a strong G Jinfeng, G Haibo, G 100 Shanghai local shares by such a strong rise in the market to generate the "Shanghai "hot situation. Shanghai to do more enthusiasm for local stocks have been successfully activated, G in Section (600.49 thousand) as a Shanghai local pharmaceutical stocks, followed by city, worthy of attention.
From the industry point of view, since China's accession to WTO since the plate subjected to a far-reaching medical implications. Tariffs reduced; pharmaceuticals intellectual property protection; open pharmaceutical wholesale and retail services, etc. are all a great country to stimulate the development of the pharmaceutical industry, but also revealed the Government's commitment to medicine. Faced with the challenge of foreign intervention and related enterprises are also expanding their use of the full transition period, this growth process, the stock market itself has also been given a great opportunity. As early Sinopharm shares, Westlands biology, have staged a share price times the effect of turning huge profits. While the same medicine as a small-cap stocks, G in Section (600.49 thousand), particularly its anti-AI makes the subject matter itself has great potential for expansion.
G, Section (600.49 thousand) is high-tech enterprises in Shanghai, mainly engaged in pharmaceutical intermediates, pesticide intermediates and organic fine chemicals and new materials production and sale of products, including anti-AIDS drug intermediates, pharmaceutical intermediates a new generation of antibacterial , anti-tumor, anti-cardiovascular disease drug intermediates, a variety of fluorine-containing organic fine chemicals and new materials as well as other products a total of more than 50. According to the company pre-announcement, the company decided to invest in spending huge sums, including an annual output of 100 tons of anti-AIDS drug intermediates "02A" technological transformation projects, including expansion of the four projects, 02A is the production of anti-AIDS drug Sustiva effects important intermediate. Once these four projects in production, will greatly increase the profits of the company's sales. Meanwhile, the company's products anti-AIDS drug intermediates, pharmaceutical intermediates a new generation of anti-bacterial, anti-tumor, anti-cardiovascular disease drug intermediates, a variety of fluorine-containing organic fine chemicals and new materials are the highest value in the development of the most active part. The main products of its anti-AIDS pharmaceutical intermediates 02A and anti-bacterial drug intermediates 245, is the world's a small number of large-scale production enterprises. The company has increased efforts to develop the international market in the United States established a sales center, from the past, the adoption of a single sales agent into sales and direct sales agents combined.
It is worth noting that the company has to Jiang Xi Sangdi and Dexing in Section replenishment to optimize the product mix to form a reasonable industrial layout shape. The main products in the section Dexing methyl chloride, methyl sulfonic acid in China has a strong market share, this capital increase is expected to achieve its main profits increased significantly.
The secondary market, G in Section (600.49 thousand) the total capital stock is only more than 8000 million, while the Shanghai local shares, stocks of living comparison, relatively small market value of the Unit have a considerable reorganization of strong expectations, huge potential for expansion . Recently, the unit is heavy volume modest rise in price with the ideal amount, at present the Unit has re-formed a rising trend, stock prices steadily higher, afternoon broke out around the corner.
